Checkpoint Inhibitor Immunotherapy Delays Colorectal Cancer Progression
In June 2020, the FDA approved the immunotherapy drug Keytruda as the first-line (initial) treatment instead of chemotherapy for patients with inoperable or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer. These features are hallmarks of most Lynch Syndrome tumors.